With the exception of KRAS mutation testing for Stage IV CRC, current clinical practice for the management of CRC does not involve an assessment of a tumor’s molecular phenotype; however, recognizing that CRC is a heterogeneous disease, there are great opportunities to improve CRC prognosis by better incorporating information on tumor biology into treatment decisions and the design of targeted treatment strategies. This evidence concerns the gene KRAS and neoplasm.